MS drug ibudilast demonstrated a 26% reduction in confirmed disability progression in progressive MS trial
Biopharmaceutical Company MediciNova has announced additional positive clinical data from its SPRINT-MS phase IIB trial of MN-166 (ibudilast) in progressive multiple sclerosis (PMS)...Read more - http://www.ms-uk.org/ms-drug-ibudilast- ... e-ms-trial
Ibudilast 26% reduction in confirmed disability progression
Ibudilast 26% reduction in confirmed disability progression
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1948 Views
-
Last post by frodo
-
- 0 Replies
- 646 Views
-
Last post by frodo
-
- 0 Replies
- 1093 Views
-
Last post by NHE
-
- 0 Replies
- 2477 Views
-
Last post by NHE
-
- 0 Replies
- 1405 Views
-
Last post by NHE
-
- 0 Replies
- 2498 Views
-
Last post by NHE
-
- 0 Replies
- 1470 Views
-
Last post by NHE
-
- 0 Replies
- 1148 Views
-
Last post by frodo
-
- 0 Replies
- 1194 Views
-
Last post by NHE